On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]

The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bank of New York Mellon Corp purchased a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 395,907 shares of the company

Price-action only: Cormedix Inc. (CRMD) movements set the tone for institutional models. The Technical Signals Behind (CRMD) That Institutions Follow

Obtenga las últimas novedades sobre el precio de las acciones y las acciones de CorMedix Inc (NASDAQ: CRMD) en Kalkine. Acceda a los últimos movimientos, comentarios de expertos y consejos generales de inversión sobre CorMedix Inc (NASDAQ:CRMD) en Kalkine.

Empowered Funds LLC acquired a new stake in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 243,232 shares of the company

Obtenga las últimas novedades sobre el precio de las acciones y las acciones de CorMedix Inc (NASDAQ: CRMD) en Kalkine. Acceda a los últimos movimientos, comentarios de expertos y consejos generales de inversión sobre CorMedix Inc (NASDAQ:CRMD) en Kalkine.

PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026. Wells Fargo 21st Annual Healthcare ConferenceDate:Time:Webca

BlackRock Inc. purchased a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,324,111 shares of the company

Get the latest CorMedix Inc. (CRMD) stock news and headlines to help you in your trading and investing decisions.

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company

CFO Susan Blum used 8,424 CorMedix shares at $8.30 to cover tax or exercise costs, leaving her with 124,315 shares, the Form 4 shows.

Chief legal officer Beth Zelnick Kaufman used 8,424 CorMedix shares, valued at $8.30 each, to cover equity-award costs, leaving 260,684 shares after Form 4.

Los ingresos de DefenCath alcanzaron los 66,1 millones de dólares a medida que CorMedix amplía sus asociaciones de diálisis y avanza en REZZAYO.